Karyopharm Therapeutics Inc. short interest in 2025
In 2025, Karyopharm Therapeutics Inc.'s disclosed short interest ran from 15.80% of shares outstanding on 15 Jan 2025 to 4.08% on 31 Dec 2025, a change of -11.72 percentage points. The year's high was 26.03% on 30 Sep 2025 and its low 3.45% on 15 Dec 2025, averaging 17.74% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 53.34 days on 30 Jun 2025. Full history: Karyopharm Therapeutics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 15.80% (15 Jan 2025)
- End of year
- 4.08% (31 Dec 2025)
- Change
- -11.72 pp
- High
- 26.03% (30 Sep 2025)
- Low
- 3.45% (15 Dec 2025)
- Average
- 17.74%
- Highest days to cover
- 53.34 (30 Jun 2025)
- SEC filings marked
- 10
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 15.80% | 22.48 | results (8-K) |
| 31 Jan 2025 | 16.07% | 30.52 | |
| 14 Feb 2025 | 16.47% | 24.94 | |
| 15 May 2025 | 24.17% | 22.25 | 10-K filed, results (8-K), 10-Q filed, results (8-K) |
| 30 May 2025 | 24.00% | 28.52 | |
| 13 Jun 2025 | 23.41% | 25.35 | |
| 30 Jun 2025 | 23.49% | 53.34 | |
| 15 Jul 2025 | 23.94% | 7.41 | |
| 31 Jul 2025 | 24.62% | 14.09 | |
| 15 Aug 2025 | 24.73% | 7.91 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 25.16% | 15.63 | |
| 15 Sep 2025 | 25.42% | 30.17 | |
| 30 Sep 2025 | 26.03% | 19.64 | |
| 15 Oct 2025 | 16.59% | 3.32 | results (8-K) |
| 31 Oct 2025 | 7.48% | 4.71 | |
| 14 Nov 2025 | 8.26% | 7.33 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 3.94% | 2.99 | |
| 15 Dec 2025 | 3.45% | 1.33 | |
| 31 Dec 2025 | 4.08% | 1.27 |
See also: Karyopharm Therapeutics Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.